225 Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.

Sanjana BallalMadhav P YadavRanjit K SahooMadhavi TripathiSada N DwivediChandrasekhar Bal

Published in: The Prostate (2021)

Treatment with 225 Ac-PSMA-617 TAT demonstrated biochemical response, improved survival, caused low treatment-related toxicity proving a promising salvage treatment option in mCRPC patients.

Keyphrases

squamous cell carcinoma
chronic kidney disease
small cell lung cancer
end stage renal disease
computed tomography
pet ct
combination therapy
replacement therapy
pet imaging